Scientific Program

검색
Session VII (C).
Satellite Symposium III (A). Room A
(Grand Ballroom 3)
Date & Time November 7(Fri), 08:20-09:00
Chair(s) TBD
Speaker
TBD

TBD

Session VII (C).
Session V (A). Novel immunotherapies beyond the PD1 pathway Room A
(Grand Ballroom 3)
Date & Time November 7(Fri), 09:10-10:10
Chair(s) Dong-Wan Kim (Seoul National Univ., Korea),
Aron Lisberg (University of California, USA)
Speaker
09:10-09:25
Beyond PD-L1 axis inhibition: Where are we going?

Aron Lisberg (University of California, USA)

09:25-09:40
Bispecifics and T cell engagers: Fighting against immune desert

Jeongmin Seo (Seoul National Univ., Korea)

09:40-09:55
Combining ICIs with ADCs is the way to go?

Sun Min Lim (Yonsei Univ., Korea)

09:55-10:10
Cellular therapies: Breaking the glass ceiling?

Ben Creelan (H. Lee Moffitt Cancer Center & Research Institute, USA)

Session VII (C).
Session VI (A). Challenges during immunotherapy Room A
(Grand Ballroom 3)
Date & Time November 7(Fri), 10:25-11:25
Chair(s) Jae Cheol Lee (Univ. of Ulsan., Korea),
Jordi Remon Masip (Institut Gustave Roussy, France)
Speaker
10:25-10:40
Should we exclude immunotherapy in case of advanced NSCLC with oncogenic addiction?

Jordi Remon Masip (Institut Gustave Roussy, France)

10:40-10:55
When can or should anti-PD(L)-1 be stopped in advanced NSCLC?

Jun Hyeok Lim (Inha Univ., Korea)

10:55-11:10
Is it feasible to restart immunotherapy after severe immune-related toxicity?

Jinyong Kim (Sungkyunkwan Univ., Korea)

11:10-11:25
Immunotherapy and brain metastases

Thomas John (Peter MacCallum Cancer Centre, Australia)

Session VII (C).
Session VII (A). Surgery in the chemoimmunotherapy era: Global perspectives Room A
(Grand Ballroom 3)
Date & Time November 7(Fri), 13:50-14:50
Chair(s) Suk Ki Cho (Seoul National Univ., Korea),
Alessandro Brunelli (St. James's University Hospital, UK)
Speaker
13:50-14:05
Refining surgical boundaries after neoadjuvant therapy in lung cancer

Samina Park (Seoul National Univ., Korea)

14:05-14:20
Optimal nodal management strategies after induction therapy: Scope, challenges, and surgical precision

Mong-Wei Lin (National Taiwan University Hospital, Taiwan)

14:20-14:35
Managing pCR in lung cancer: the evolving role of ctDNA in postoperative strategy

Jeonghwan Youk (Seoul National Univ., Korea)

14:35-14:50
Real-world surgical outcomes after neoadjuvant chemoimmunotherapy: The European experience

Alessandro Brunelli (St. James's University Hospital, UK)

Session VII (C).
Session VIII (A). Stage-Specific considerations and dilemmas Room A
(Grand Ballroom 3)
Date & Time November 7(Fri), 15:05-16:05
Chair(s) Gong Yong Jin (Jeonbuk National Univ., Korea),
Jong Ho Cho (Sungkyunkwan Univ., Korea)
Speaker
15:05-15:25
Imaging controversies in lung cancer staging

Won Gi Jeong (Chonnam National Univ., Korea)

15:25-15:45
Systematic EBUS Staging to guide therapy

June hong Ahn (Yeungnam Univ., Korea)

15:45-16:05
Should yp-staging be defined in future editions of the TNM classification system?

Young Tae Kim (Seoul National Univ., Korea)